Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).
Video Player is loading.
Play Video
Play
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:00
1x
Playback Rate
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions settings, opens captions settings dialog
captions off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone
Close Modal Dialog
End of dialog window.
Close Modal Dialog
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Data from the following clinical trials are discussed:
1373M0 - JUPITER-06: A randomized, double-blind, phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC) (JUPITER-06)
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase 3 ORIENT-15 study (ORIENT-15)
Newsletter
Stay up to date on the most recent and practice-changing oncology data